{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:03:32Z","timestamp":1773331412533,"version":"3.50.1"},"reference-count":33,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>Aim.<\/jats:title>\n                  <jats:p>To compare early (&amp;lt;3 days) with late (&amp;gt;15 days) steroid therapy and dexamethasone with inhaled budesonide in very preterm infants at risk of developing chronic lung disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Five hundred seventy infants from 47 neonatal intensive care units were enrolled. Criteria for enrollment included gestational age &amp;lt;30 weeks, postnatal age &amp;lt;72 hours, and need for mechanical ventilation and inspired oxygen concentration &amp;gt;30%. Infants were randomly allocated to 1 of 4 treatment groups in a factorial design: early (&amp;lt;72 hours) dexamethasone, early budesonide, delayed selective (&amp;gt;15 days) dexamethasone, and delayed selective budesonide. Dexamethasone was given in a tapering course beginning with 0.50 mg\/kg\/day in 2 divided doses for 3 days reducing by half until 12 days of therapy had elapsed. Budesonide was administered by metered dose inhaler and a spacing chamber in a dose of 400 \u03bcg\/kg twice daily for 12 days. Delayed selective treatment was started if infants needed mechanical ventilation and &amp;gt;30% oxygen for &amp;gt;15 days. The factorial design allowed 2 major comparisons: early versus late treatment and systemic dexamethasone versus inhaled budesonide. The primary outcome was death or oxygen dependency at 36 weeks and analysis was on an intention-to-treat basis. Secondary outcome measures included death or major cerebral abnormality, duration of oxygen treatment, and complications of prematurity. Adverse effects were also monitored daily.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>There were no significant differences among the groups for the primary outcome. Early steroid treatment was associated with a lower primary outcome rate (odds ratio [OR]: 0.85; 95% confidence interval [CI]: 0.61,1.18) but even after adjustment for confounding variables the difference remained nonsignificant. Dexamethasone-treated infants also had a lower primary outcome rate (OR: 0.86; 95% CI: 0.62,1.20) but again this difference remained not significant after adjustment. For death before discharge, dexamethasone and early treatment had worse outcomes than budesonide and delayed selective treatment (OR: 1.42; 95% CI: 0.93,2.16; OR: 1.51; 95% CI: 0.99,2.30 after adjustment, respectively) with the results not quite reaching significance. Duration of supplementary oxygen was shorter in the early dexamethasone group (median: 31 days vs 40\u201344 days). Early dexamethasone was also associated with increased weight loss during the first 12 days of treatment (52 g vs 3 g) compared with early budesonide, but over 30 days there was no difference. In the early dexamethasone group, there was a reduced incidence of persistent ductus arteriosus (34% vs 52%\u201359%) and an increased risk of hyperglycemia (55% vs 29%\u201334%) compared with the other 3 groups. Dexamethasone was associated with an increased risk of hypertension and gastrointestinal problems compared with budesonide but only the former attained significance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Infants given early treatment and dexamethasone therapy had improved survival without chronic lung disease at 36 weeks compared with those given delayed selective treatment and inhaled budesonide, respectively, but results for survival to discharge were in the opposite direction; however, none of these findings attained statistical significance. Early dexamethasone treatment reduced the risk of persistent ductus arteriosus. Inhaled budesonide may be safer than dexamethasone, but there is no clear evidence that it is more or less effective.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.107.2.232","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"232-240","source":"Crossref","is-referenced-by-count":74,"title":["A Multicenter, Randomized Open Study of Early Corticosteroid Treatment (OSECT) in Preterm Infants With Respiratory Illness: Comparison of Early and Late Treatment and of Dexamethasone and Inhaled Budesonide"],"prefix":"10.1542","volume":"107","author":[{"given":"Henry L.","family":"Halliday","sequence":"first","affiliation":[{"name":"From the Regional Neonatal Unit, Royal Maternity Hospital andDepartments of Child Health and Epidemiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris C.","family":"Patterson","sequence":"additional","affiliation":[{"name":"Public Health, The Queen's University of Belfast, Belfast, Northern Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrishanti W. N. L.","family":"Halahakoon","sequence":"additional","affiliation":[{"name":"From the Regional Neonatal Unit, Royal Maternity Hospital andDepartments of Child Health and Epidemiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on Behalf of the European Multicenter Steroid Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2001,2,1]]},"reference":[{"key":"2021121009493218200_B1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJM199303253281208","article-title":"Pulmonary surfactant therapy.","volume":"328","author":"Jobe","year":"1993","journal-title":"N Engl J Med"},{"key":"2021121009493218200_B2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128072-199901010-00003","article-title":"Current perspectives on the drug treatment of neonatal respiratory distress syndrome.","volume":"1","author":"Sweet","year":"1999","journal-title":"Pediatr Drugs"},{"key":"2021121009493218200_B3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF01955247","article-title":"Reduction in the risk of bronchopulmonary dysplasia from 1980\u20131990: results of a multivariate logistic regression analysis.","volume":"152","author":"Corcoran","year":"1993","journal-title":"Eur J Pediatr"},{"key":"2021121009493218200_B4","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1542\/peds.105.6.1194","article-title":"Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease?","volume":"105","author":"Van Marter","year":"2000","journal-title":"Pediatrics"},{"key":"2021121009493218200_B5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1542\/peds.101.5.856","article-title":"Health and developmental outcomes at 18 months in very preterm infants with bronchopulmonary dysplasia.","volume":"101","author":"Gregoire","year":"1998","journal-title":"Pediatrics"},{"key":"2021121009493218200_B6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-200022050-00006","article-title":"A risk-benefit assessment of drugs used for neonatal chronic lung disease.","volume":"22","author":"Sweet","year":"2000","journal-title":"Drug Safety"},{"key":"2021121009493218200_B7"},{"key":"2021121009493218200_B8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/adc.68.3_Spec_No.330","article-title":"The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.","volume":"68","author":"Ng","year":"1993","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0022-3476(98)70431-7","article-title":"Too many unvalidated new therapies to prevent chronic lung disease in preterm infants.","volume":"132","author":"Jobe","year":"1998","journal-title":"J Pediatr"},{"key":"2021121009493218200_B10","first-page":"421","article-title":"Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial.","volume":"88","author":"Collaborative Dexamethasone Trial Group","year":"1991","journal-title":"Pediatrics"},{"key":"2021121009493218200_B11"},{"key":"2021121009493218200_B12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000047044","article-title":"Clinical trials of postnatal corticosteroids: inhaled and systemic.","volume":"76","author":"Halliday","year":"1999","journal-title":"Biol Neonate"},{"key":"2021121009493218200_B13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1203\/00006450-199407001-00022","article-title":"Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome.","volume":"36","author":"Sanders","year":"1994","journal-title":"Pediatr Res"},{"key":"2021121009493218200_B14","doi-asserted-by":"crossref","first-page":"F33","DOI":"10.1136\/fn.74.1.F33","article-title":"Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome.","volume":"74","author":"Shinwell","year":"1996","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B15"},{"key":"2021121009493218200_B16"},{"key":"2021121009493218200_B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1203\/00006450-199807000-00017","article-title":"The influence of betamethasone and dexamethasone on motor development in young rats.","volume":"44","author":"Gramsbergen","year":"1998","journal-title":"Pediatr Res"},{"key":"2021121009493218200_B18"},{"key":"2021121009493218200_B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.104.1.15","article-title":"Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.","volume":"104","author":"O'Shea","year":"1999","journal-title":"Pediatrics"},{"key":"2021121009493218200_B20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/adc.65.8.906","article-title":"Aerosol therapy in the newborn.","volume":"65","author":"Silverman","year":"1990","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B21","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM199904013401304","article-title":"Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.","volume":"340","author":"Cole","year":"1999","journal-title":"N Engl J Med"},{"key":"2021121009493218200_B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/adc.67.1_Spec_No.25","article-title":"Delivery of therapeutic aerosols to intubated babies.","volume":"67","author":"Grigg","year":"1992","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0140-6736(93)92296-6","article-title":"The CRIB (Clinical Risk Index for Babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care hospitals.","volume":"342","author":"The International Neonatal Network","year":"1993","journal-title":"Lancet"},{"key":"2021121009493218200_B24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/adc.69.3_Spec_No.276","article-title":"Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial).","volume":"66","author":"Halliday","year":"1993","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B25","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1136\/fn.73.1.F1","article-title":"Inflammatory mediators and bronchopulmonary dysplasia.","volume":"73","author":"Groneck","year":"1995","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.97.2.210","article-title":"Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.","volume":"97","author":"Watterberg","year":"1996","journal-title":"Pediatrics"},{"key":"2021121009493218200_B27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1164\/ajrccm.157.1.9604014","article-title":"Ventilator-induced lung injury.","volume":"157","author":"Dreyfuss","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121009493218200_B28","first-page":"1","article-title":"A review of postnatal corticosteroids for treatment and prevention of chronic lung disease in the preterm infant.","volume":"2","author":"Halliday","year":"1997","journal-title":"Prenat Neonat Med"},{"key":"2021121009493218200_B29","doi-asserted-by":"crossref","first-page":"F26","DOI":"10.1136\/fn.79.1.F26","article-title":"Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease.","volume":"79","author":"Bhuta","year":"1998","journal-title":"Arch Dis Child"},{"key":"2021121009493218200_B30","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0022-3476(09)90024-5","article-title":"Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheo-bronchial aspirates of infants at risk for chronic lung disease.","volume":"122","author":"Groneck","year":"1993","journal-title":"J Pediatr"},{"key":"2021121009493218200_B31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0095-5108(18)30143-X","article-title":"Treatment of bronchopulmonary dysplasia.","volume":"25","author":"Barrington","year":"1998","journal-title":"Clin Perinatol"},{"key":"2021121009493218200_B32","doi-asserted-by":"crossref","first-page":"226A","DOI":"10.1203\/00006450-199904020-01345","article-title":"Early postnatal dexamethasone therapy for the prevention of chronic lung disease.","volume":"45","author":"Soll","year":"1999","journal-title":"Pediatr Res"},{"key":"2021121009493218200_B33"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/107\/2\/232\/892992\/232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/107\/2\/232\/892992\/232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T21:53:21Z","timestamp":1639173201000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/107\/2\/232\/66305\/A-Multicenter-Randomized-Open-Study-of-Early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2001,2,1]]},"published-print":{"date-parts":[[2001,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.107.2.232","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}